AMGN ought to be considered a Big Pharma—I think it was silly of Barron’s to exclude them from the article. GILD has almost as high a market cap as LLY, so it could be considered a Big Pharma based on valuation; however, it’s almost never pigeonholed that way because it started out as an antiviral specialist and has only gradually expanded into other areas.
By the way, the table accompanying the Barron’s article has an egregious error. I’ll make this a quiz :- )
Market Data 
Markets 
AI
